US Treatment-Resistant Depression Drugs Market Industry Trends and Forecast to 2034: Segmented by (Drug Class, Route, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Overview
Market Dashboard
US · 2024–2034 · placeholder estimates
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the
full report.
Estimate 2024$878.3 MnPlaceholder estimate
Estimate 2025$931.9 Mn39.9% of the global market
Projected 2034$1.59 Bn 70.4%Adds $655.9 Mn over 9 forecast years
CAGR 2025–20346.1%Faster than 51% of 180 Pharmaceuticals markets here
Key players5
US is 39.95% of the global market.
In North America, the largest is US (this report) at $931.9 Mn.
77 in the USSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the US. Retrieved 12 Nov 2026.
Formats
PDF, PPTX, XLSX
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
The US Treatment-Resistant Depression Drugs Market Analysis Executive Summary
Treatment-resistant depression drugs help people whose depression has not improved with at least two standard antidepressants.
Key segments of the treatment-Resistant Depression Drugs market include drug class (NMDA Antagonists, Atypical Antipsychotic Add-Ons and Psychedelics) and route (Oral, Intranasal and Intravenous).
US Treatment-Resistant Depression Drugs market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.
US Treatment-Resistant Depression Drugs Market Dynamics
Market Growth Drivers
More people seeking help for mental health, less stigma, better screening and new treatments with faster effects are driving the treatment-Resistant Depression Drugs market. Governments and employers are investing more in mental health care.
Opportunity
Digital tools, new drug classes and care built into primary care and workplaces give the treatment-Resistant Depression Drugs market strong room to grow worldwide.
Market Restraints
Shortages of mental health professionals, limited insurance coverage, side effects and the need for long-term treatment hold back the treatment-Resistant Depression Drugs market.
Competitive Landscape for Treatment-Resistant Depression Drugs Market in US
The treatment-Resistant Depression Drugs market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Healthcare Policies and Regulatory Landscape for Treatment-Resistant Depression Drugs Market in US
Treatment-Resistant Depression Drugs in the US: rules, payment and research
New drugs need approval from the US Food and Drug Administration (FDA); many over-the-counter medicines are sold under FDA monographs instead.[1] Medicare covers people aged 65 and over and some younger people with disabilities, and Medicaid covers many people on low incomes; both are run with the Centers for Medicare & Medicaid Services (CMS).[2] ClinicalTrials.gov lists 77 studies on Treatment-Resistant Depression Drugs that are recruiting, active or about to start in the US.[3] Suicide rate: 14.0 per 100,000 people in 2023, the latest WHO figure for the US.[4]
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for treatment-Resistant Depression Drugs. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in US.
2.2 Market Size, Growth Prospects and Key findings
3 Market Dynamics
3.1 Market Growth Drivers Analysis
3.2 Market Restraints Analysis
4 Market Segmentation
4.1 By Drug Class
4.2 By Route
4.3 By End User
5 By Market Share
5.1 Market Analysis, Insights and Forecast – By Revenue
6 Competitive Landscape
6.1 Major Top Market Players Products in Pipeline
6.2 R&D Initiatives
6.3 Notable recent Deals
6.3.1 Strategic Divestments
6.3.2 Mergers & Acquisitions
6.3.3 Partnerships
6.3.4 Joint Ventures
7 Key Company Profiles
7.1 Johnson & Johnson (Janssen)
7.2 AbbVie
7.3 Otsuka Pharmaceutical
7.4 Axsome Therapeutics
7.5 Compass Pathways
8 Healthcare Policies and Regulatory Landscape
8.1 Policy changes and Reimbursement scenario
8.2 Government Initiatives / Intervention programs
The treatment-Resistant Depression Drugs market can be segmented based on various criteria, including drug class, route and end user. Here's a breakdown of the market segmentation
Other companies that free public records show in this market: trials they lead, US approvals and WHO prequalification. They are not part of our key players research. Each count opens its source.
Also active in this area, from free public records
Source: ClinicalTrials.gov, Active studies (recruiting, about to start or running) each company leads, found with this market's trial search, worldwide. Retrieved 13 Nov 2026.
Source: Drugs@FDA, US approvals each company holds for medicines on the market whose FDA label lists this use. Retrieved 13 Nov 2026.
Beyond the market numbers
Research, trials and patients
What doctors and scientists are doing in Treatment-Resistant Depression Drugs right now, from free public sources.
How big is the Treatment-Resistant Depression Drugs market in the US?
Placeholder estimate: about $931.9 Mn in 2025, rising to about $1.59 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Treatment-Resistant Depression Drugs market in the US growing?
Placeholder estimate: about 6.1% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Treatment-Resistant Depression Drugs market report cover?
The report splits the market by drug class (NMDA Antagonists, Atypical Antipsychotic Add-Ons, Psychedelics, Others), route (Oral, Intranasal, Intravenous) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Treatment-Resistant Depression Drugs market?
Key players include Johnson & Johnson, AbbVie Inc., Otsuka Pharmaceutical Co., Ltd., Axsome Therapeutics and Compass Pathways.
What is driving the Treatment-Resistant Depression Drugs market?
More people seeking help for mental health, less stigma, better screening and new treatments with faster effects are driving the treatment-Resistant Depression Drugs market. Governments and employers are investing more in mental health care.
Who regulates Treatment-Resistant Depression Drugs in the US?
New drugs need approval from the US Food and Drug Administration (FDA); many over-the-counter medicines are sold under FDA monographs instead. Source: US Food and Drug Administration. Checked 14 Nov 2026.
How is healthcare paid for in the US?
Medicare covers people aged 65 and over and some younger people with disabilities, and Medicaid covers many people on low incomes; both are run with the Centers for Medicare & Medicaid Services (CMS). Source: Centers for Medicare & Medicaid Services. Checked 14 Nov 2026.
How many clinical trials on Treatment-Resistant Depression Drugs are running in the US?
77 studies are recruiting, active or about to start in the US, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the US. Retrieved 12 Nov 2026.
What does WHO report for the US?
Suicide rate: 14.0 per 100,000 people in 2023, the latest WHO figure. Source: WHO Global Health Observatory, Suicide rate (per 100,000 people). Retrieved 15 Nov 2026.
How many people in the US are 65 or older?
18.4% of people were 65 or older in 2025. Source: World Bank Open Data, Population ages 65 and above (% of total population), from UN population estimates. Retrieved 18 Nov 2026.